Earn CME: https://naccme.com/program/7313
In this presentation from the ‘New Horizons in the Treatment of Relapsed and Refractory Myeloma symposium, Dr. Adriana C. Rossi discusses whether to use a three- or four-drug regimen as induction therapy for a fit patient with relapsed and refractory myeloma.
© 2018 Imedex, an HMP Company